Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 20;12(1):177.
doi: 10.1186/s40478-024-01887-9.

Detection of diagnostic somatic copy number alterations from cerebrospinal fluid cell-free DNA in brain tumor patients

Svenja Klinsing  1   2 , Julia Beck  3 , Katharina J Weber  4   5   6   7 , Kirsten Bornemann-Kolatzki  3 , Mareike Dettki  1 , Hans Urban  1   5   6   7 , Bastian Roller  1   5   6   7 , Kai U Chow  8 , Henning Reis  9 , Peter J Wild  9 , Ekkehard Schuetz  3 , Philipp Euskirchen  10   11 , Joachim P Steinbach  1   5   6   7 , Michael W Ronellenfitsch  1   5   6   7 , Patrick N Harter  4   12   13 , Pia S Zeiner  14   15   16   17   18
Affiliations

Detection of diagnostic somatic copy number alterations from cerebrospinal fluid cell-free DNA in brain tumor patients

Svenja Klinsing et al. Acta Neuropathol Commun. .

Abstract

The gold standard for precise diagnostic classification of brain tumors requires tissue sampling, which carries relevant procedural risks. Brain biopsies often have limited sensitivity and fail to address tumor heterogeneity, because small tissue parts are being examined. This study aims to explore the detection and quantification of diagnostically relevant somatic copy number aberrations (SCNAs) in cell-free DNA (cfDNA) extracted from cerebrospinal fluid (CSF) in a real-world cohort of patients with defined brain tumor subtypes. A total of 33 CSF samples were collected from 30 patients for cfDNA extraction. Shallow whole-genome sequencing was conducted on CSF samples containing > 3ng of cfDNA and corresponding tissue DNA from nine patients. The sequencing cohort encompassed 26 samples of 23 patients, comprising 12 with confirmed CNS cancer as compared to 11 patients with either ambiguous CNS lesions (n = 5) or non-cancer CNS lesions (n = 6). After mapping and quality filtering SCNAs were called by depth-of-coverage analyses with a binning of 5.5 Mbp. SCNAs were exclusively identified in CSF cfDNA from brain tumor patients (10/12, 83%). In tumor patients, SCNAs were detectable in cfDNA from all patients with, but also in five of seven patients without tumor cells detected by CSF cytopathology. A substantial number of shared SCNAs were traceable between tissue and CSF in matched pair analyses. Additionally, some SCNAs unique to either CSF or tissue indicating spatial heterogeneity or tumor evolution. Also, diagnostically relevant genomic alterations as well as essential and desirable SCNAs as implemented in the current WHO classification of CNS tumors for certain primary brain tumor subtypes were traceable. In summary, this minimally invasive cfDNA-based LB approach employing shallow whole genome sequencing demonstrates potential for providing a molecularly informed diagnosis of CNS cancers, mapping tumor heterogeneity, tracking tumor evolution, and surveilling tumor patients. Further prospective trials are warranted.

Keywords: Brain tumor; Cell-free DNA; Cerebrospinal fluid; Liquid biopsy; Next-generation sequencing.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This retrospective investigation and use of patient material and data was approved by the Ethics Committee of the University Hospital Frankfurt (SNO-9-2022). Consent for publication: Not applicable. Competing interests: NGS was conducted and analyzed at Chronix Biomedical by JB, KBK and ES, who are employees of Chronix Biomedical an Oncocyte Company. JPS has received honoraria for lectures, advisory board participation, consulting, and travel grants from Abbvie, Roche, Boehringer, Bristol-Myers Squibb, Medac, Mundipharma, and UCB. PJW has received consulting fees and honoraria for lectures by Bayer, Sanofi, Janssen-Cilag, Novartis, Roche, MSD, Astellas Pharma, Bristol-Myers Squibb, Thermo Fisher Scientific, Molecular Health, Guardant Health, Sophia Genetics, Qiagen, Eli Lilly, Myriad, Hedera Dx, and Astra Zeneca and research support was provided by Astra Zeneca and Roche. HR received honoraria from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Chop GmbH, Diaceutics, GlaxoSmithKline, HUeG, Janssen-Cilag, MCI, Merck, Novartis, Roche Pharma, Sanofi and Wolfsburg Klinikum and funding from Bristol-Myers Squibb. MWR has received a research grant from UCB. PSZ has received a lecture honorarium from Bristol-Myers Squibb. The remaining authors declare that the research was carried out without any commercial or financial relationships that could potentially create a conflict of interest.

Figures

Fig. 1
Fig. 1
Study workflow and consort diagram. A Study workflow. CSF, cerebrospinal fluid; DNA, Deoxyribonucleic acid. B The consort flow diagram illustrates the study approach leading to a real-life cohort of patients with different types of CNS cancers with the purpose of analyzing somatic copy number aberrations (SCNAs) through next-generation sequencing
Fig. 2
Fig. 2
Somatic copy number aberrations in cell-free DNA from cerebrospinal fluid of patients with CNS cancers. A Overview clinical diagnosis and SCNA parameters. CSF cfDNA SCNA positivity vs. negativity and comparison of SCNA profiles in CSF and corresponding tissue (shared SCNAs) are depicted. B Frequency of detection of somatic copy number aberrations (SCNAs) across various CNS cancer types. SCNA positive samples are shown in green, negative samples in red. C SCNA parameters (CNI score, aberrant bin count, tumor cfDNA fraction) across the tumor patients. D Circos plots showing the copy number profile of cfDNA from cerebrospinal fluid of three exemplarily tumor patients with a high or medium CNI score in contrast to a patient without SCNAs
Fig. 3
Fig. 3
Correlation of CSF liquid biopsies with sampling and clinical variables. Box-plots depict the distribution of the NGS parameters (CNI score, aberrant bin count, tumor cfDNA fraction) considering defined sampling and clinical variables. Significant p-values < 0.05 are shown in the charts, otherwise no statistically significant differences were observed. LB = liquid biopsy; PD = progressive disease, LMD = leptomeningeal disease, cytology-confirmed; ref. = reference; CSF = cerebrospinal fluid.
Fig. 4
Fig. 4
Diagnostic value of SCNA profiling of cell-free DNA from cerebrospinal fluid of patients with CNS cancers. A Concordance analyses between CSF and tumor tissue. Depicted is the fraction of SCNAs private to CSF (blue), private to tissue (gray) or shared between the two (red). B Circos plots with copy number profiles of CSF cfDNA compared to tissue DNA exemplifying the usefulness of SNCA profiling for minimal invasive detection of CNS cancer, molecularly informed diagnostic assessment, mapping of tumor heterogeneity and tracking tumor evolution as well as surveilling patients with a previous cancer diagnosis
See this image and copyright information in PMC

References

    1. Soffietti R, Bettegowda C, Mellinghoff IK, Warren KE, Ahluwalia MS, De Groot JF et al (2022) Liquid biopsy in gliomas: a RANO review and proposals for clinical applications. Neuro Oncol 24:855–871 - PMC - PubMed
    1. Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, Junck L et al (2019) Liquid biopsy in central nervous system metastases: A RANO review and proposals for clinical applications. Neuro Oncol 21:571–583 - PMC - PubMed
    1. Nayak L, Bettegowda C, Scherer F, Galldiks N, Ahluwalia M, Baraniskin A et al (2024) Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: a RANO review. Neuro Oncol 26:993–1011 - PMC - PubMed
    1. Seoane J, De Mattos-Arruda L, Le RE, Bardelli A, Weller M (2019) Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann Oncol 30:211–8 - PubMed
    1. Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N et al (2019) Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature 565:654–658 - PMC - PubMed

Publication types

LinkOut - more resources